ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Genocea Biosciences Inc (CE)

Genocea Biosciences Inc (CE) (GNCAQ)

0.000001
0.00
(0.00%)
Closed November 05 4:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.000001
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.000001 52 Week Range 0.0002
Previous Close
0.000001
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
1,572
Financial Volume
-
VWAP
-

GNCAQ Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1001.0E-61.0E-61.0E-630991.0E-6CS
4001.0E-60.00011.0E-617129.02E-6CS
12001.0E-60.00011.0E-615721.485E-5CS
26001.0E-60.00011.0E-622916.35E-6CS
52001.0E-60.00021.0E-6163279.183E-5CS
156-9.9E-5-990.00010.00741.0E-6157410.00046723CS
260-9.9E-5-990.00010.00741.0E-6157410.00046723CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRCOGreenbelt Resources Corporation (CE)
$ 0.0003
(29,900.00%)
48.59k
LLBOLifeline Biotech Inc (CE)
$ 0.0002
(19,900.00%)
2.4k
GMPRGourmet Provisions International Corporation (PK)
$ 0.0001
(9,900.00%)
42.73M
MRNJMetatron Inc (PK)
$ 0.0001
(9,900.00%)
1.11M
ATTOFAtento SA (CE)
$ 0.0001
(9,900.00%)
100
LZGILZG International Inc (CE)
$ 0.000001
(-99.98%)
3k
FBECFBEC Worldwide Inc (CE)
$ 0.000001
(-99.88%)
750k
KBNTKubient Inc (CE)
$ 0.000001
(-99.67%)
951
EGIOQEdgio Inc (CE)
$ 0.0001
(-99.67%)
1.05k
EMRHEmerging Holdings Inc (PK)
$ 0.0001
(-99.67%)
1.5k
RDARRaadr Inc (PK)
$ 0.00085
(-10.53%)
230.71M
PHILPHI Group Inc (PK)
$ 0.0001
(-50.00%)
226.64M
VTXBVortex Brands Company (PK)
$ 0.0003
(-25.00%)
128.47M
HMBLHUMBL Inc (PK)
$ 0.0003
(0.00%)
128.41M
AITXArtificial Intelligence Technology Solutions Inc (PK)
$ 0.00265
(-1.85%)
114.26M

GNCAQ Discussion

View Posts
Renee Renee 2 years ago
Effective Dec. 23,2022 GNCA will change to GNCAQ, bankruptcy.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
πŸ‘οΈ0
MVick MVick 2 years ago
Comeback time
πŸ‘οΈ0
swampboots swampboots 2 years ago
DTIL covers with better money and partners similar territory/platforms, so just holding for positives before the necessary negatives.
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
The collab is focused on advancing multiple existing and additional next gen allo CAR-T programs directed to haematological malignancies. RHHBY has an exclusive license to anti-BCMA and anti-CD19/CD20 programs. Exclusive option to anti-CD70 and anti-BCMA/CD19 programs, as well as the right to nominate six additional candidates.
πŸ‘οΈ0
swampboots swampboots 2 years ago
PSTX
πŸ‘οΈ0
Milo1 Milo1 2 years ago
$62M in valuation, assets and cash, and selling for $1.2M market capitalization. There is a merger coming here for sure, they are preparing this for a reverse merger, as the recent filings suggest. Somebody is buying all those shares up!
πŸ‘οΈ0
JDCruz JDCruz 2 years ago
GNCA featured in Microcapdaily : https://microcapdaily.com/genocea-biosciences-inc-otcmkts-gnca-ex-nasdaq-biotech-heating-up-and-making-moves-on-the-otc-as-co-winds-down-operations/
πŸ‘οΈ0
Renee Renee 2 years ago
It means whatever was in the S-8 has now become effective.
πŸ‘οΈ0
Wisebuys Wisebuys 2 years ago
What does notice of effectiveness mean?
πŸ‘οΈ0
cparma cparma 2 years ago
This is starting to tick back up now.....
πŸ‘οΈ0
Renee Renee 2 years ago
GNCA delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
cparma cparma 2 years ago
Not sure about Fraud. They just went out of business. Shut down operations and laid off everyone. Just didn't work out.
πŸ‘οΈ0
ErnieBilco ErnieBilco 2 years ago
Plain and simple - FRAUD!!!!!

The CEO and BOD should be thrown in jail for stealing salaries for nothing.
πŸ‘οΈ0
NY1972 NY1972 2 years ago
Fraud!!
πŸ‘οΈ0
ErnieBilco ErnieBilco 2 years ago
Leerink Partners should feel pretty stupid right about now.

https://www.tipranks.com/news/blurbs/genocea-biosciences-gnca-receives-a-buy-from-leerink-partners?utm_source=advfn.com&utm_medium=referral
πŸ‘οΈ0
Awl416 Awl416 2 years ago
Ouch
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
Preclinical posters

Engineering TGF-B-resistant TCR-edited T cells for mutant TP53-targeted cancer immunotherapy https://www.neogene.com/staging/wp-content/uploads/2022/04/Keystone-2022-TGFBR2-KO-TP53-R175H-TCR-poster-final-edit.pdf

Development of a personalized neoantigen specific TCR discovery platform https://www.neogene.com/staging/wp-content/uploads/2022/04/Neogene-Poster-v1-final_reduced.pdf
πŸ‘οΈ0
NY1972 NY1972 2 years ago
ATLAS worked. Planet failed.

T cells that show up in great numbers in head and neck tumors, but not in similar tissues of the mouth inflamed by common ailments such as gum disease.

It seems that this odd group of T cells have mixed up their highly specialized assignments within our immune systems and are now working to protect tumor cells.
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
PR https://www.prnewswire.com/news-releases/pact-pharma-highlights-capabilities-and-versatility-of-novel-non-viral-gene-editing-technology-in-presentation-at-american-society-of-gene--cell-therapy-asgct-25th-annual-meeting-301547277.html

Poster https://storage.googleapis.com/pact-assets/ASGCT-2022-Lu/ASGCT-2022-Lu.pdf
πŸ‘οΈ0
jondoeuk jondoeuk 2 years ago
''NT-125 is an investigational, autologous, fully-individualized, multi-specific TCR therapy targeting neoantigens for the treatment of advanced solid tumors. NT-125 is designed to contain up to five distinct neoantigen-specific TCRs per patient in a single cell product of highly functional engineered T cells, allowing multiple neoantigens presented by HLA class I and HLA class II molecules to be targeted with the goal to create a more impactful TCR therapy for more patients. NT-125 aims to reduce the probability of antigen escape and potentially maximize the depth and durability of clinical responses in a patient population with difficult to treat tumors and high unmet need.'' https://www.biospace.com/article/releases/neogene-therapeutics-announces-approval-of-clinical-trial-application-for-its-first-phase-1-trial-of-novel-fully-individualized-tcr-therapy-to-treat-advanced-solid-tumors/

Also, https://www.businesswire.com/news/home/20220111005172/en/Neogene-Therapeutics-Announces-Exclusive-License-with-the-National-Cancer-Institute-for-a-Portfolio-of-T-Cell-Receptors-TCR-Targeting-KRAS-and-TP53-Mutations-for-the-Treatment-of-Cancer
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
189: A Versatile, Non-Viral Gene Editing Method for Directing Specificity and Enhancing Function of T Cells https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1157
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Hopefully, this will play out similar to MRK buying Immune Design (from memory, they had to cut the workforce by ~20% after the lead program was discontinued).
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Biotechs are filled with frauds. Investors kept in the dark until the well runs dry.
πŸ‘οΈ0
NY1972 NY1972 3 years ago
CEO knew Planet failed when DP was made for cohort A.
πŸ‘οΈ0
NY1972 NY1972 3 years ago
NPT turned out to be a lost TIL. 10000 pg promised, 1000 pg IFN actual
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Turnstone Bio https://www.businesswire.com/news/home/20220425005377/en/Turnstone-Biologics-Announces-TIL-Therapy-Research-Collaboration-with-the-University-of-Montreal-Hospital-Research-Centre
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
By Q4 (GEN-011)

20-24 patients dosed.

Day 57 scans from 14-18 patients.

Up to 10 patients on schedule B3 (TIL-like).

Day 113 scans from 9-11 patients.

Up to 8 patients on schedule B3 (TIL-like).

Tumour mix: NSCLC, SCCHN, UC, and melanoma likely to predominate.

Biomarker data: ctDNA, tumour infiltration, TCR sequencing and proliferation and persistence.
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
From this: ''Using high-dimensional analysis of human ACT products, we identified a memory-progenitor CD39-negative stem-like phenotype (CD39-CD69-) associated with complete cancer regression and TIL persistence and a terminally differentiated CD39-positive state (CD39+CD69+) associated with poor TIL persistence.'' https://www.science.org/doi/10.1126/science.abb9847

Also, ''With a median potential follow-up of 89 months, 46 of 48 complete responders in the aPD-1-naïve cohort have ongoing responses after a single treatment and 10-year melanoma-specific survival of 96%.'' https://aacrjournals.org/clincancerres/article-abstract/27/19/5289/671696/Impact-of-Prior-Treatment-on-the-Efficacy-of

Hopefully, a trial testing these double negative TIL in melanoma, as well as other types will be underway soon.
πŸ‘οΈ0
NY1972 NY1972 3 years ago
young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978753/#SD1
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02006-4
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors
There was a robust upregulation of T cells, macrophages, CD8+ T cells, and cytotoxic gene signatures in responders. Additionally, responders had an increase in Th1 gene signatures; an increase in TGF-ß1 gene expression was also noted. In distant lesions, the same gene signatures were upregulated.

https://acir.org/weekly-digests/2022/april/aacr-annual-meeting-2022#therapies
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Mellman described published work linking PD-1 and CD28 signaling through the phosphatase Shp2. Evidence also showed that myeloid cells, particularly dendritic cells in the TME, were the critical source of PD-L1 ligand.

https://acir.org/weekly-digests/2022/april/aacr-annual-meeting-2022#therapies
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Bio chop suey : Orca-T is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors.
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
The poster

πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Speaking of GvHD, Orca Bio (an IPO could be in the works) https://www.businesswire.com/news/home/20211211005011/en/Positive-Clinical-Results-from-More-than-100-Patients-Treated-with-Orca-Bio’s-Lead-Investigational-High-Precision-Cell-Therapy-Presented-at-63rd-ASH-Annual-Meeting

A PhIII (in AML, ALL and MDS) should be underway soon.
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
Some slides from a presentation given at ESMO '21 on the MAYA trial (eoesophageal types are MGMT low. Another group is investigating the approach in the ELEVATE trial).





πŸ‘οΈ0
NY1972 NY1972 3 years ago
High-Dose Cyclophosphamide Reduces Graft-Versus-Host Disease Following Stem Cell Transplantation

https://www.practiceupdate.com/content/ash-2019-high-dose-cyclophosphamide-reduces-graft-versus-host-disease-following-stem-cell-transplantation/94022
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Emergence of tumor mismatch repair deficiency and increased mutational burden in blood and tissue of metastatic colorectal cancer patients treated with temozolomide

https://www.abstractsonline.com/pp8/#!/10517/presentation/20869

https://ascopubs.org/doi/full/10.1200/JCO.21.02583
πŸ‘οΈ0
NY1972 NY1972 3 years ago
The reason high-dose cyclophosphamide is able to ablate the effector cells without destroying hematopoietic stem cells is that the earliest stem cells (but not lymphocytes) contain high levels of aldehyde dehydrogenase conferring resistance to the cytoxic properties of cyclophosphamide. Dr. Brodsky and his colleagues in neurology and rheumatology are applying this approach in other severe autoimmune disorders including, scleroderma, myasthenia gravis, multiple sclerosis and autoimmune hematologic disorders.

https://ashpublications.org/blood/article/115/11/2136/27022/High-dose-cyclophosphamide-for-severe-aplastic
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
NeoPhore is developing first-in-class small molecule inhibitors to specifically block the MMR pathway in solid tumours. The company's scientific co-founders and SAB members Drs. Alberto Bardelli and Luis Diaz on new research showing that pharmacological inhibition of DNA mismatch repair can conceptually enhance patient responses to immunotherapy https://www.science.org/content/article/surprising-strategy-would-fight-mutant-cancer-cells-making-more-mutations
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

https://ashpublications.org/bloodadvances/article/6/7/1969/483864/Fludarabine-exposure-predicts-outcome-after-CD19
πŸ‘οΈ0
NY1972 NY1972 3 years ago
MC = 64 doses CAR T
πŸ‘οΈ0
NY1972 NY1972 3 years ago
T cells CPD

https://bmcimmunol.biomedcentral.com/articles/10.1186/s12865-021-00435-7

πŸ‘οΈ0
NY1972 NY1972 3 years ago
GNCA Buyers and sellers feel like TILS
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Last Smart Money left the bldg. only dummies stick around.
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Analysis of severe lymphodepletion on the day of TIL infusion as measured by absolute lymphocyte counts showed similar values when comparing the high-dose and low-dose cyclophosphamide/fludarabine groups (0.029 ± 0.036 K/L [median, 0.020 K/L] vs 0.024 ± 0.017 K/L [median, 0.025 K/L]).

https://www.healio.com/news/hematology-oncology/20210820/highdose-lymphodepletion-regimen-effective-but-more-toxic-for-patients-receiving-tils?msclkid=2e42737cc10911ecbba737c4032a5800
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849715/
πŸ‘οΈ0
NY1972 NY1972 3 years ago
Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780711/
πŸ‘οΈ0
NY1972 NY1972 3 years ago
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492314/#sd
πŸ‘οΈ0
jondoeuk jondoeuk 3 years ago
A PhI trial (NCT04217473) is assessing an 'armed' (encodes for hTNF-a and hIL-2) OV in R/R stage III/IV melanoma patients, who cannot be treated with curative intent and are eligible for TIL therapy. Patients receive TILT-123 intravenously and intratumorally, and TIL therapy without LD chemo or high-dose IL-2 https://www.businesswire.com/news/home/20220330005560/en/TILT-Biotherapeutics-Announces-Positive-Update-on-its-Phase-1-Immunotherapy-Clinical-Trials-in-Cancer
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock